Uncategorized
Ocular Therapeutix addresses most FDA concerns about Dextenza NDA
Ocular Therapeutix provided an update on its new drug application for Dextenza, according to a press release.In July, the FDA raised concerns in a complete response letter regarding deficiencies in the manufacturing process and controls that were identified during a pre-NDA approval inspection of the company’s manufacturing facility.